



<b>Title</b>	<b>Positron Emission Tomography for Cardiovascular Disease: A Review of the Clinical Effectiveness</b>
<b>Agency</b>	CADTH, Canadian Agency for Drugs and Technologies in Health Suite 600, 865 Carling Ave, Ottawa, Ontario K1S 5S8 Canada; Tel: +1 613 226 2553, Fax: +1 613 226 5392; publications@cadth.ca, www.cadth.ca
<b>Reference</b>	2010

## **Aim**

To assess the clinical effectiveness of positron emission tomography (PET) in diagnosing and managing coronary artery disease (CAD); and to identify and assess the quality of the guidelines for using PET to diagnose and manage CAD.

## **Conclusions and results**

PET was found to be a useful tool in diagnosing CAD, particularly in patients with an intermediate likelihood of CAD, those who are obese, or those unable to exercise. The role of PET in identifying patients with CAD who might benefit from revascularization is unclear. A lack of evidence from studies with high internal validity and the quality of the evidence used by guideline development groups may be a consideration when deciding to use PET to diagnose or manage patients with CAD.

## **Methods**

A literature search encompassed key health technology assessment resources, international health technology agencies, and a focused Internet search. The search was limited to articles published in English. Filters were applied to limit the retrieval to systematic reviews, health technology assessments, meta-analyses, randomized controlled trials, controlled clinical trials, observational studies, and guidelines. Two independent reviewers screened articles using predefined criteria. Any disagreements were resolved through discussion until consensus was achieved.